| As of Monday, November 23rd: |
LATEST EARNINGS RESULTS
- More Consumers Giving 'Black Friday' the Cold Shoulder
- Prepare For Large Decline In Stocks, Next Year?
- Tuesday's Heavy Dose of Data to Dictate 'Risk' Behavior
- Hewlett-Packard Earnings Rise, Match Guidance
- HP Comes in As Expected; Is It Time to Buy?
- Cramer: What Monday’s Housing Number Really Means
- Why the Dollar Will Likely Stay Weak for Some Time
- Bear, Lehman Execs Weren't Wiped Out by Crisis: Study
- How Real Estate Investors Skew Housing's Reality
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- HP Comes in As Expected; Is It Time to Buy?
- Prepare For Large Decline In Stocks, Next Year?
- Hewlett-Packard Profit Rises, Matches Guidance
- Wave of Debt Payments Facing US Government
- Nov. 23: Unusual Volume Leaders
- Paul: Audit the Fed
- The Social Media Gaming Threat
- Holiday Travel Outlook
- Lyondell Urged to Consider Reliance Takeover Offer
Text Size 
Bristol-Myers Squibb on Thursday posted a 29 percent jump in second-quarter profit due to higher sales of several key products and significant cost-cutting that overcame effects of the strong dollar.
The maker of blood thinner Plavix, the world's second-bestselling medicine, and psychiatric drug Abilify said its net income was $983 million, or 49 cents per share.
That compares with $764 million, or 38 cents per share, a year earlier.
New York-based Bristol-Myers said revenue rose 3.5 percent to $5.4 billion from $5.2 billion in the second quarter of 2008.
Analysts polled by Thomson Reuters were expecting, on average, earnings per share of 47 cents and revenue of $5.3 billion.
The strong performance comes after the world's No. 15 drugmaker last night announced a $2.1 billion deal to buy Medarex, which owns antibody technology used to create drugs.
Sales in the Bristol-Myers pharmaceutical division rose 4 percent, to $4.67 billion.
Revenue from the company's share of the Mead Johnson nutrition business was flat at $719 million.
"We are well on track to continue delivering on our growth commitments," Chief Executive James M. Cornelius said in a statement. "Our business performance and financial strength position us well to invest in further opportunities for long-term growth."
Cornelius said the Medarex deal is another example of the Bristol-Myers strategy, dubbed String of Pearls, to acquire biotechnology drugs and companies and transform its technological capabilities.
 |
CNBC.com Bristol-Myers Earnings |
Bristol-Myers lowered the high end of its 2009 profit forecast, sending a new range of $1.58 to $1.68 per share, compared with the prior $1.58 to $1.73.
Excluding one-time charges, the company raised its forecast slightly, to $1.95 to $2.05, from $1.85 to $2.
While many of its competitors have seen flat or down revenue this quarter because of unfavorable exchange rates, Bristol-Myers said they only reduced total revenue by 5 percent.
In addition, Bristol-Myers only gets a little more than one-third of its sales overseas, while many global drugmakers draw a roughly half their revenue from foreign countries, giving currency rates a bigger impact.
For the first six months, Bristol-Myers posted net income of $1.62 billion, or 81 cents per share. That was up 14 percent from $1.43 billion, or 71 cents a share, in the first half of 2008.
Shares in Bristol-Myers Squibb [BMY
Loading...
()
] rose 12 cents to $20.41 in early morning trade on Thursday after the Medarex announcement late Wednesday.
- Analog Devices Results Beat Expectations; Shares Rise
Analog Devices reported a quarterly profit that fell from a year ago but topped Wall Street's expectations, sending shares higher in extended trading.
- Tyson Food Profit Beats Estimates
Tyson Foods posted higher-than-expected quarterly results on Monday on strength in its beef, pork and prepared foods businesses, which it expects to continue in its new fiscal year.
- Horton Results Miss Estimates, Shares Drop
D.R. Horton, the No. 2 U.S. homebuilder, reported a much larger-than-expected quarterly loss on Friday, sending its shares down nearly 7 percent even though it also said orders increased.
- Analog Devices Results Beat Expectations; Shares Rise
- Dell Shares Smacked as Earnings, Sales Miss Forecasts
The computer maker reported financial results that were worse than last year and also fell short of Wall Street expectations, punishing the company's shares.
- Dell Shares Smacked as Earnings, Sales Miss Forecasts
- Gap Reports Earnings in Line With Forecasts
- Intuit Posts Narrower-Than-Expected Loss
- Sears Posts Second Consecutive Quarterly Loss
- BJ's Wholesale Profit Falls, Hurt by Falling Food Prices
- Salesforce Profit Beats Forecasts, but Shares Fall
- Autodesk Shares Fall on Disappointing Outlook
- Home Depot Profit Beats; Says Markets Under Pressure
- Target Third Quarter Profit Up, Cautious on Fourth
- Weak US Housing Market Drags on Lowe's Profit
- JC Penney Profit Falls, but Shares Up on Forecast
- Disney Profit, Sales Top Forecasts; Shares Jump
- Nordstrom Earnings Miss Forecasts; Shares Take Hit
- Wal-Mart Holiday Forecast Light, Profit Beats
- Kohl's Profit Beats Street, But Outlook Falls Short
- Vivendi Profit Up More Than 5%, Keeps 2009 Goals
Data is a real-time snapshot *Data is delayed at least 15 minutes